These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 30926088)

  • 1. The emerging role of measurable residual disease detection in AML in morphologic remission.
    Buccisano F; Maurillo L; Schuurhuis GJ; Del Principe MI; Di Veroli A; Gurnari C; Venditti A
    Semin Hematol; 2019 Apr; 56(2):125-130. PubMed ID: 30926088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimal/Measurable Residual Disease Detection in Acute Leukemias by Multiparameter Flow Cytometry.
    Fuda F; Chen W
    Curr Hematol Malig Rep; 2018 Dec; 13(6):455-466. PubMed ID: 30446941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methods of Detection of Measurable Residual Disease in AML.
    Zhou Y; Wood BL
    Curr Hematol Malig Rep; 2017 Dec; 12(6):557-567. PubMed ID: 29098609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection and management of acute myeloid leukemia measurable residual disease: is it standard of care?
    Paterno G; Del Principe MI; Venditti A
    Curr Opin Hematol; 2020 Mar; 27(2):81-87. PubMed ID: 31895104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Prognostic Significance of Measurable ("Minimal") Residual Disease in Acute Myeloid Leukemia.
    Buccisano F; Hourigan CS; Walter RB
    Curr Hematol Malig Rep; 2017 Dec; 12(6):547-556. PubMed ID: 29027628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurement of Residual Disease in Acute Myeloid Leukemia.
    Vedula RS; Lindsley RC
    Curr Hematol Malig Rep; 2017 Dec; 12(6):574-581. PubMed ID: 29064024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia.
    Cloos J; Harris JR; Janssen JJWM; Kelder A; Huang F; Sijm G; Vonk M; Snel AN; Scheick JR; Scholten WJ; Carbaat-Ham J; Veldhuizen D; Hanekamp D; Oussoren-Brockhoff YJM; Kaspers GJL; Schuurhuis GJ; Sasser AK; Ossenkoppele G
    J Vis Exp; 2018 Mar; (133):. PubMed ID: 29553571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal Measurable Residual Disease Testing for Acute Myeloid Leukemia.
    Xiao W; Petrova-Drus K; Roshal M
    Surg Pathol Clin; 2019 Sep; 12(3):671-686. PubMed ID: 31352980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurable residual disease in acute myeloid leukemia using flow cytometry: approaches for harmonization/standardization.
    Schuurhuis GJ; Ossenkoppele GJ; Kelder A; Cloos J
    Expert Rev Hematol; 2018 Dec; 11(12):921-935. PubMed ID: 30466339
    [No Abstract]   [Full Text] [Related]  

  • 10. The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation.
    Wang Z; Guo M; Zhang Y; Xu S; Cheng H; Wu J; Zhang W; Hu X; Yang J; Wang J; Tang G
    Int J Lab Hematol; 2019 Oct; 41(5):607-614. PubMed ID: 31162830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimal residual disease as a biomarker for outcome prediction and therapy optimization in acute myeloid leukemia.
    Buccisano F; Maurillo L; Del Principe MI; Di Veroli A; De Bellis E; Biagi A; Zizzari A; Rossi V; Rapisarda V; Amadori S; Voso MT; Lo-Coco F; Arcese W; Venditti A
    Expert Rev Hematol; 2018 Apr; 11(4):307-313. PubMed ID: 29495904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
    Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
    Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MRD in AML: does it already guide therapy decision-making?
    Ossenkoppele G; Schuurhuis GJ
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):356-365. PubMed ID: 27913502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of RNA- and DNA-based methods for measurable residual disease analysis in NPM1-mutated acute myeloid leukemia.
    Pettersson L; Johansson Alm S; Almstedt A; Chen Y; Orrsjö G; Shah-Barkhordar G; Zhou L; Kotarsky H; Vidovic K; Asp J; Lazarevic V; Saal LH; Fogelstrand L; Ehinger M
    Int J Lab Hematol; 2021 Aug; 43(4):664-674. PubMed ID: 34053184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia.
    Buccisano F; Maurillo L; Del Principe MI; Del Poeta G; Sconocchia G; Lo-Coco F; Arcese W; Amadori S; Venditti A
    Blood; 2012 Jan; 119(2):332-41. PubMed ID: 22039260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Impact of Unsupervised Early Assessment of Bulk and Leukemic Stem Cell Measurable Residual Disease in Acute Myeloid Leukemia.
    Canali A; Vergnolle I; Bertoli S; Largeaud L; Nicolau ML; Rieu JB; Tavitian S; Huguet F; Picard M; Bories P; Vial JP; Lechevalier N; Béné MC; Luquet I; Mansat-De Mas V; Delabesse E; Récher C; Vergez F
    Clin Cancer Res; 2023 Jan; 29(1):134-142. PubMed ID: 36318706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of minimal residual disease in the management of acute myeloid leukemia-a case-based discussion.
    Coltoff A; Houldsworth J; Keyzner A; Renteria AS; Mascarenhas J
    Ann Hematol; 2018 Jul; 97(7):1155-1167. PubMed ID: 29704019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A mind map for managing minimal residual disease in acute myeloid leukemia.
    Benton CB; Ravandi F
    Clin Adv Hematol Oncol; 2017 Nov; 15(11):859-867. PubMed ID: 29200419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication.
    Tiong IS; Loo S
    Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimal residual disease in acute myeloid leukemia: coming of age.
    Paietta E
    Hematology Am Soc Hematol Educ Program; 2012; 2012():35-42. PubMed ID: 23233558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.